CN Patent

CN109843339B — 影响肿瘤杀伤的双重靶向构建体

Assigned to Cornell University · Expires 2023-07-07 · 3y expired

What this patent protects

本技术涉及与表达PSMA的癌症的治疗有关的化合物、组合物、药物和方法。该化合物为式I&II或其药学上可接受的盐。本技术尤其适用于在治疗前列腺癌中的应用。

USPTO Abstract

本技术涉及与表达PSMA的癌症的治疗有关的化合物、组合物、药物和方法。该化合物为式I&II或其药学上可接受的盐。本技术尤其适用于在治疗前列腺癌中的应用。

Drugs covered by this patent

lutetium-lu-177-vipivotide-tetraxetan (LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN)

Patent Metadata

Patent number: CN109843339B
Jurisdiction: CN
Classification: —
Expires: 2023-07-07
Drug substance claim: No
Drug product claim: No
Assignee: Cornell University
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.